Edition:
Deutschland

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

15.28HKD
24 Nov 2017
Change (% chg)

HK$0.18 (+1.19%)
Prev Close
HK$15.10
Open
HK$15.20
Day's High
HK$15.44
Day's Low
HK$15.00
Volume
3,934,515
Avg. Vol
6,961,071
52-wk High
HK$16.30
52-wk Low
HK$7.17

1530.HK

Chart for 1530.HK

About

3SBio Inc. is an investment holding company, principally engaged in the development, production, marketing and sale of pharmaceutical products in Mainland China. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries,... (more)

Buy/Sell

Sell Hold Buy
1.89 Mean rating from 19 analysts

Overall

Beta: --
Market Cap(Mil.): HK$34,730.74
Shares Outstanding(Mil.): 2,538.80
Dividend: --
Yield (%): --

BRIEF-3SBio Inc says 601a approved by China FDA for clinical trials ​

* Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​ Source text for Eikon: Further company coverage:

Deals of the day-Mergers and acquisitions

Sept 5 The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Tuesday:

Chinese biopharma 3SBio in $290 million deal for unit of Canada's Therapure

SHANGHAI China's 3SBio Inc has agreed to buy the contract development and manufacturing unit of Canada's Therapure Biopharma Inc for $290 million, part of a push by the Chinese biotech company into the North American market.

Chinese biopharma 3SBio in $290 mln deal for unit of Canada's Therapure

SHANGHAI, Sept 4 China's 3SBio Inc has agreed to buy the contract development and manufacturing unit of Canada's Therapure Biopharma Inc for $290 million, part of a push by the Chinese biotech company into the North American market.

BRIEF-3Sbio says HY net profit rose about 34.3 pct

* HY net profit rose about 34.3 pct to about RMB389.6 million

REFILE-BRIEF-3SBio Inc plans to issue 300 mln euros convertible bonds

* Proposed Issue Of Euro 300,000,000 Zero Coupon Convertible Bonds Due 2022

BRIEF-3SBio says unit proposes to issue euro-denominated convertible bonds

* Unit strategic international group proposes to conduct an international offering of euro-denominated convertible bonds Source text for Eikon: Further company coverage:

BRIEF-3SBio Inc TPIAO being received approval for drug clinical trials

* TPIAO, one of products of group, has been granted approval for drug clinical trials for additional indications issued by china food and drug administration Source text for Eikon: Further company coverage:

BRIEF-3Sbio Inc updates on marketing authorization for group's product EPIAO

* Group has received marketing authorization for group's product EPIAO from ministry of health of Ukraine Source text for Eikon: Further company coverage:

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.45%
Rohstoffe +0.03%
Industrie +0.19%
Konjunktur abhängige Waren & Dienstleistungen +0.09%
Konjunktur unabhängige Waren & Dienstleistungen +0.09%
Finanzindustrie +0.18%
Pharma +0.49%
Technologie +0.31%
Telekommunikation +0.10%